Ticker Details
Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
IPO Date:	April 28, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$297.81M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 3.28%
Avg Daily Range (30 D):	$0.12 | 2.50%
Avg Daily Range (90 D):	$0.16 | 3.29%

Institutional Daily Volume
Avg Daily Volume:	.52M
Avg Daily Volume (30 D):	.7M
Avg Daily Volume (90 D):	.85M

Trade Size
Avg Trade Size (Sh.):	140
Avg Trade Size (Sh.) (30 D):	92
Avg Trade Size (Sh.) (90 D):	102

Institutional Trades
Total Institutional Trades:	447
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$.65M
Avg Institutional Trade (90 D):	$.83M
Avg Institutional Trade Volume:	.23M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.9M
Avg Closing Trade (30 D):	$.65M
Avg Closing Trade (90 D):	$.86M
Avg Closing Volume:	253.9K

News

May 15, 2025 @ 1:00 AM Bragar Eagel & Squire, P.C. Is Investigating Organ... Source: N/A

May 3, 2025 @ 11:18 AM ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:... Source: N/A

Apr 29, 2025 @ 1:00 AM Bragar Eagel & Squire, P.C. Is Investigating TechT... Source: N/A

Apr 27, 2025 @ 12:20 PM ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NAS... Source: N/A

Apr 25, 2025 @ 4:57 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-.13	$-.16
Diluted EPS		$-.13	$-.16
Revenue
Gross Profit
Net Income / Loss		$-7.69M	$-9.77M
Operating Income / Loss		$-8M	$-10.17M
Cost of Revenue
Net Cash Flow		$18.1M	$-9.11M
PE Ratio